Market Snapshot

S&P Futures
4,401.75
Dow Futures
34,931.00
NASDAQ Futures
15,099.25

24.73$3.93 18.89%
Market open    14:28:24 pm   
From: To:

Stock Snapshot

20.80
Prev. Close
38.58
Open
94.22M
Market Cap
42680.00
Number of Shares
21.25
Day Low
38.75
Day High
24.73
-
P/E Ratio
3.09M
Free Float in %
-0.45
EPS 2021
1.39
Book Value per Share
1.34
Cash Flow per Share
NeuroMetrix, Inc. (NURO)
NeuroMetrix, Inc. (NURO) stock rallied over 18.89% intraday to trade at $24.73 per share on NASDAQ. The stock opened with a gain of 85.48% at $38.58 and touched an intraday high of $38.75, rising 86.30% against the last close of $20.80. The stock went to a low of $21.25 during the session.

Historical Prices

DateOpenCloseAdj. CloseDaily HighDaily LowVolume
2021-06-30$3.38$3.41$3.41$3.49$3.3687,757
2021-06-29$3.62$3.50$3.50$3.62$3.4352,600
2021-06-28$3.70$3.58$3.58$3.73$3.5070,000
2021-06-25$3.70$3.70$3.70$3.77$3.6482,800
2021-06-24$3.67$3.70$3.70$3.70$3.5668,800
2021-06-23$3.42$3.60$3.60$3.63$3.3874,800
2021-06-22$3.48$3.39$3.39$3.48$3.3433,200
2021-06-21$3.64$3.48$3.48$3.64$3.4283,500
2021-06-18$3.74$3.63$3.63$3.75$3.55120,600
2021-06-17$3.61$3.80$3.80$3.80$3.60188,900
2021-06-16$3.58$3.66$3.66$3.68$3.43360,800
NeuroMetrix, Inc.
4B Gill Street
Woburn, MA 01801
United States

http://www.neurometrix.com
781 890 9989
Employees
20
Sector
Healthcare
Sales or Revenue
Industry
Medical Instruments & Supplies
5Y Sales Change
0.20
Fiscal Year Ends
2020-12-30
Dr. Shai N. Gozani
Founder, Chairman, CEO, Pres & Sec.
Mr. Thomas T. Higgins
Sr. VP, CFO & Treasurer
Mr. Michael J. MacDonald
Sr. VP of Commercial Operations & GM of Diagnostics
NeuroMetrix, Inc.
NeuroMetrix, Inc., a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; ADVANCE system, a platform for the performance of traditional nerve conduction studies; and SENSUS, a pain therapy device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain. The company offers its products to consumers, retail merchandisers, direct response TV promoters, health care professionals, managed care organizations, endocrinologists, podiatrists, physicians, neurologists, and physical medicine and rehabilitation centers, as well as primary care, internal medicine, orthopedic, hand, and neurosurgeons. It operates in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has a strategic collaboration with GlaxoSmithKline. NeuroMetrix, Inc. was founded in 1996 and is based in Woburn, Massachusetts.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam